Reduced oxidative damage in ALS by high-dose enteral melatonin treatment (Q34571459)

3 August 2017

Reduced oxidative damage in ALS by high-dose enteral melatonin treatment (English)

1 reference

amyotrophic lateral sclerosis

3 August 2017

0 references

1 reference

11

1 reference

3 August 2017

16

Klaus-Armin Nave

1 reference

3 August 2017

17

Hannelore Ehrenreich

0 references

Anna-Leena Sirén

object named as

Anna-Leena Sirén

13

0 references

Rüdiger Hardeland

14

object named as

Rüdiger Hardeland

1 reference

3 August 2017

Jochen H Weishaupt

1

1 reference

3 August 2017

Claudia Bartels

2

1 reference

3 August 2017

Esther Pölking

3

1 reference

3 August 2017

Jeannine Dietrich

4

1 reference

3 August 2017

Gundula Rohde

5

1 reference

3 August 2017

Burkhard Poeggeler

6

1 reference

3 August 2017

Nina Mertens

7

1 reference

3 August 2017

Swetlana Sperling

8

1 reference

3 August 2017

Matthias Bohn

9

1 reference

3 August 2017

Gerald Hüther

10

1 reference

3 August 2017

Alfred Bach

12

1 reference

3 August 2017

Mathias Bähr

15

1 reference

3 August 2017

1 November 2006

1 reference

Journal of Pineal Research

3 August 2017

1 reference

3 August 2017

41

1 reference

3 August 2017

313-323

1 reference

3 August 2017

4

1 reference

Amyotrophic lateral sclerosis

3 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

From Charcot to SOD1: mechanisms of selective motor neuron death in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Unraveling the mechanisms involved in motor neuron degeneration in ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Glutamate receptors: RNA editing and death of motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Glutamate neurotoxicity and diseases of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Cellular circadian clocks in the pineal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Development and characterisation of a glutamate-sensitive motor neurone cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Trk receptors: roles in neuronal signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Superoxide dismutase protects cultured neurons against death by starvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

First-time-in-human dose selection: allometric thoughts and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Oxidatively modified proteins in aging and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Regulation of antioxidant enzymes: a significant role for melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Vitamin E intake and risk of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Melatonin mitigates mitochondrial malfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Of mice and not men: differences between mouse and human immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Minocycline delays disease onset and mortality in a transgenic model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Efficient three-drug cocktail for disease induced by mutant superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-079X.2006.00377.X

10.1111/J.1600-079X.2006.00377.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference